ST Elevation Myocardial Infarction (STEMI)

Also known as: STEMI - ST Elevation Myocardial Infarction / ST-Elevation Myocardial Infarction / (STEMI) / ST-elevation Myocardial Infarction (STEMI) / ST Elevation (STEMI) Myocardial Infarction / STEMI / Acute myocardial infarction NOS / Acute transmural myocardial infarction of unspecified site / Acute myocardial infarction, unspecified site, episode of care unspecified / Acute myocardial infarction, unspecified site / Acute myocardial infarction / Myocardial infarction acute / ST segment elevation myocardial infarction

DrugDrug NameDrug Description
DB00758ClopidogrelClopidogrel, an antiplatelet agent structurally and pharmacologically similar to ticlopidine, is used to inhibit blood clots in a variety of conditions such as peripheral vascular disease, coronary artery disease, and cerebrovascular disease. Clopidogrel is sold under the name Plavix by Sanofi and Bristol-Myers Squibb. The drug is an irreversible inhibitor of the P2Y12 adenosine diphosphate receptor found on the membranes of platelet cells. Clopidogrel use is associated with several serious adverse drug reactions such as severe neutropenia, various forms of hemorrhage, and cardiovascular edema.
DB00569FondaparinuxFondaparinux (Arixtra) is a synthetic anticoagulant agent consisting of five monomeric sugar units and a O-methyl group at the reducing end of the molecule. It is structurally similar to polymeric glycosaminoglycan heparin and heparan sulfate (HS) when they are cleaved into monomeric units. The monomeric sequence in heparin and HS is thought to form the high affinity binding site for the natural anti-coagulant factor, antithrombin III (ATIII). Once bound to heparin or HS, the anticoagulant activity of ATIII is potentiated by 1000-fold. Fondaparinux potentiates the neutralizing action of ATIII on activated Factor X 300-fold. Fondaparinux may be used: to prevent venous thromboembolism in patients who have undergone orthopedic surgery of the lower limbs (e.g. hip fracture, hip replacement and knee surgery); to prevent VTE in patients undergoing abdominal surgery who are are at high risk of thromboembolic complications; in the treatment of deep vein thrombosis (DVT) and pumonary embolism (PE); in the management of unstable angina (UA) and non-ST segment elevation myocardial infarction (NSTEMI); and in the management of ST segment elevation myocardial infarction (STEMI).
DB01109HeparinUnfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (factor IIa) and factor Xa. UH is different from low molecular weight heparin (LMWH) in the following ways: the average molecular weight of LMWH is about 4.5 kDa whereas it is 15 kDa for UH; UH requires continuous infusions; activated partial prothrombin time (aPTT) monitoring is required when using UH; and UH has a higher risk of bleeding and higher risk of osteoporosis in long term use. Unfractionated heparin is more specific than LMWH for thrombin. Furthermore, the effects of UH can typically be reversed by using protamine sulfate.
DB00031TenecteplaseTenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at amino acids 296-299 in the protease domain.
DrugDrug NameTargetType
DB00758ClopidogrelP2Y purinoceptor 12target
DB00758ClopidogrelCytochrome P450 3A4enzyme
DB00758ClopidogrelCytochrome P450 2B6enzyme
DB00758ClopidogrelCytochrome P450 3A5enzyme
DB00758ClopidogrelCytochrome P450 2C19enzyme
DB00758ClopidogrelCytochrome P450 2C9enzyme
DB00758ClopidogrelCytochrome P450 1A2enzyme
DB00758ClopidogrelCytochrome P450 2C8enzyme
DB00758ClopidogrelLiver carboxylesterase 1enzyme
DB00758ClopidogrelMultidrug resistance protein 1transporter
DB00758ClopidogrelSolute carrier family 22 member 1transporter
DB00758ClopidogrelSolute carrier family 22 member 2transporter
DB00569FondaparinuxAntithrombin-IIItarget
DB00569FondaparinuxCoagulation factor Xtarget
DB01109HeparinAntithrombin-IIItarget
DB01109HeparinCoagulation factor Xtarget
DB01109HeparinP-selectintarget
DB01109HeparinHeparanaseenzyme
DB01109HeparinFibroblast growth factor receptor 4target
DB01109HeparinFibroblast growth factor 4target
DB01109HeparinFibroblast growth factor 19target
DB01109HeparinFibroblast growth factor receptor 1target
DB01109HeparinFibroblast growth factor 1target
DB01109HeparinFibroblast growth factor receptor 2target
DB01109HeparinFibroblast growth factor 2target
DB01109HeparinPlatelet factor 4target
DB01109HeparinHepatocyte growth factortarget
DB01109HeparinThyroxine-binding globulincarrier
DB00031TenecteplaseUrokinase plasminogen activator surface receptortarget
DB00031TenecteplasePlasminogen activator inhibitor 1target
DB00031TenecteplaseFibrinogen alpha chaintarget
DB00031TenecteplasePlasminogen activator inhibitor 2target
DB00031TenecteplaseTetranectintarget
DB00031TenecteplaseKeratin, type II cytoskeletal 8target
DB00031TenecteplaseAnnexin A2target
DB00031TenecteplaseCalreticulintarget
DB00031TenecteplaseCalnexintarget
DB00031TenecteplaseProlow-density lipoprotein receptor-related protein 1target
DB00031TenecteplasePlasminogentarget
DrugDrug NamePhaseStatusCount
DB00640Adenosine2Completed1
DB12054BQ-1232Completed1
DB06441Cangrelor2Recruiting1
DB11723Dutogliptin2Enrolling by Invitation1
DB11981Elamipretide2Completed1
DB00063Eptifibatide2Terminated1
DB00099Filgrastim2Enrolling by Invitation1
DB00435Nitric Oxide2Terminated1
DB12003Thymosin beta-42Suspended1
DB00331Metformin2 / 3Completed1
DB06209Prasugrel2 / 3Completed1
DB01076Atorvastatin3Unknown Status1
DB00758Clopidogrel3Completed1
DB09140Oxygen3Completed1
DB06209Prasugrel3Completed2
DB08816Ticagrelor3Completed1
DB00054Abciximab4Unknown Status2
DB00316Acetaminophen4Recruiting1
DB01076Atorvastatin4Unknown Status1
DB00006Bivalirudin4Recruiting3
DB00006Bivalirudin4Unknown Status1
DB06441Cangrelor4Not Yet Recruiting1
DB06441Cangrelor4Recruiting1
DB00758Clopidogrel4Unknown Status1
DB00758Clopidogrel4Withdrawn1
DB06695Dabigatran etexilate4Withdrawn1
DB01225Enoxaparin4Recruiting1
DB00813Fentanyl4Recruiting1
DB01109Heparin4Recruiting2
DB06800Methylnaltrexone4Completed1
DB00946Phenprocoumon4Withdrawn1
DB06209Prasugrel4Recruiting1
DB06209Prasugrel4Unknown Status1
DB06228Rivaroxaban4Withdrawn1
DB01098Rosuvastatin4Recruiting1
DB00641Simvastatin4Recruiting1
DB09153Sodium chloride4Completed1
DB09153Sodium chloride4Recruiting1
DB00031Tenecteplase4Recruiting1
DB08816Ticagrelor4Completed2
DB08816Ticagrelor4Not Yet Recruiting1
DB00775Tirofiban4Recruiting2
DB00054AbciximabNot AvailableUnknown Status1
DB00009AlteplaseNot AvailableCompleted1
DB06441CangrelorNot AvailableRecruiting1
DB00086StreptokinaseNot AvailableCompleted1
DB00031TenecteplaseNot AvailableCompleted1